Oculis Holding AG (OCS) Depreciation and Depletion (2023 - 2026)
Oculis Holding AG (OCS) posted quarterly Depreciation and Depletion of $196658.7 for Q1 2026, up 43.75% year-over-year from $136806.8 in Q1 2025, and down 0.52% quarter-over-quarter from $197684.8 in Q4 2025.
Analysis
Oculis Holding AG (OCS) Depreciation and Depletion (2023 - 2026) Analysis & Trends
Oculis Holding AG's Depreciation and Depletion history runs 5 years deep, the most recent figure standing at $196658.7 for Q1 2026.
- In Q1 2026, Depreciation and Depletion rose 43.75% year-over-year to $196658.7; the TTM figure through Mar 2026 stood at $720851.8 (up 39.89% YoY), while the FY2025 annual figure was $658546.2, up 42.7% from the prior year.
- Depreciation and Depletion for Q1 2026 stood at $196658.7, down from $197684.8 in the prior quarter.
- The five-year high for Depreciation and Depletion was $207604.4 in Q4 2022, with the low at $33134.6 in Q3 2022.
- The 5-year median for Depreciation and Depletion is $136491.6 (2025), against an average of $125414.5.
- Peak annual rise in Depreciation and Depletion reached 149.43% in 2023, while the deepest fall reached 59.82% in 2023.
- Oculis Holding AG's Depreciation and Depletion stood at $207604.4 in 2022, then sank by 59.82% to $83424.2 in 2023, then surged by 66.94% to $139265.7 in 2024, then surged by 41.95% to $197684.8 in 2025, then fell by 0.52% to $196658.7 in 2026.
- Business Quant data shows OCS's Depreciation and Depletion at $196658.7 in Q1 2026, $197684.8 in Q4 2025, and $190016.6 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 225,212.56 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 225,212.56 |
| Mar 31, 2026 | 196,658.72 |
| Dec 31, 2025 | 197,684.83 |
| Sep 30, 2025 | 190,016.65 |
| Jun 30, 2025 | 136,491.60 |
| Mar 31, 2025 | 136,806.82 |
| Dec 31, 2024 | 139,265.67 |
| Sep 30, 2024 | 140,813.28 |
| Jun 30, 2024 | 98,415.62 |
| Mar 31, 2024 | 83,634.81 |
| Dec 31, 2023 | 83,424.23 |
| Sep 30, 2023 | 82,647.14 |